DURHAM, N.C. (AP) _ BioCryst Pharmaceuticals Inc. (BCRX) on Tuesday reported a loss of $42.5 million in its third quarter.

The Durham, North Carolina-based company said it had a loss of 23 cents per share.

The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 32 cents per share.

The drugmaker posted revenue of $75.8 million in the period, which also topped Street forecasts. Five analysts surveyed by Zacks expected $73.5 million.

BioCryst shares have dropped almost 4% since the beginning of the year. The stock has fallen 11% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BCRX at https://www.zacks.com/ap/BCRX

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News